Diabetologie und Stoffwechsel 2021; 16(S 01): S16-S17
DOI: 10.1055/s-0041-1727331
01. Klinische Diabetologie

Key differences with hypoglycaemic fear in people using insulin: the association with missed bolus doses exists for T2 D, but not T1D

SS Edwards
1   Eli Lilly and Company, Medical, Indianapolis, IN, United States
,
X He
1   Eli Lilly and Company, Medical, Indianapolis, IN, United States
,
J Johnson
1   Eli Lilly and Company, Medical, Indianapolis, IN, United States
,
ES Meadows
1   Eli Lilly and Company, Medical, Indianapolis, IN, United States
,
W Wang
1   Eli Lilly and Company, Medical, Indianapolis, IN, United States
,
H Wolpert
1   Eli Lilly and Company, Medical, Indianapolis, IN, United States
,
W Polonsky
2   Behavioral Diabetes Institute, Medical, San Diego, CA, United States
,
A Ponce-Ibarra
3   Lilly Deutschland GmbH, Medical, Bad Homburg, Germany
› Institutsangaben
 

Background and aims Connected insulin pens can assess missed bolus doses (MBD) and their impact on glycemic outcomes. We determined the relationship of MBD to time-in-range (TIR) and explored psychosocial factors associated with MBD.

Materials and methods This observational study enrolled people with T1 D or insulin-using T2 D (A1C≥8 %, ≥3 insulin boluses / day) and administered Hypoglycaemic Fear Survey (HFS) at baseline. MBD was calculated with connected pen and blinded CGM data with varying parameters. MBD was defined as no insulin dose from 2 hours prior to 4 hours after start of glucose excursion (> 70 mg / dl rise in glucose not preceded by hypoglycaemia [< 70mg / dL]). We fitted negative binomial models (with MBD / day as outcome) and performed model selection by Bayesian information criteria (BIC).

Results Mean age 48 years, 44 % female; 65 % had A1C≥9.0 %. T1D(n = 40) and T2D(n = 28) participants differed on age, BMI, and diabetes duration. Participants had mean 0.72 MBD / day (range 0-1.86). TIR was 42.6 % ( ± 18.8 %) (MBD negatively associated [rS=-0.28, p = 0.02]), time-above-range (TAR) was 52.8 % ( ± 21.3 %) (MBD positively associated [rS = 0.26, p = 0.03]).

For T2 D participants, MBD / day were significantly more common with: lower Worry (HFS-W [IRR = 0.94, p = 0.004]), higher Avoidance (HFS-A [IRR = 1.14, p = 0.005]), and higher Maintain High (HFS-MH [IRR = 1.07, p = 0.040]). For T1 D participants, no HFS subscales were associated with MBD / day.

Conclusion Reducing MBD may improve TIR, so it is important to understand why people miss doses. Differences between T1 D and T2 D participants regarding association of hypoglycemic fear with MBD frequency were unexpected, and addressing concerns about hypoglycemia, at least for T2 D, may be a worthwhile first step.



Publikationsverlauf

Artikel online veröffentlicht:
06. Mai 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany